Groups | Severe COVID-19 | Moderate COVID-19 | Healthy controls |
---|---|---|---|
Number of individuals (n (%)) | 10 (33.3) | 10 (33.3) | 10 (33.3) |
Age (median (IQR) | 41 (31–63) | 64 (44–65) | 49 (26–54) |
Gender (n (%)) | |||
Female | 5 (16.7) | 3 (10.0) | 5 (16.7) |
Male | 5 (16.7) | 7 (23.3) | 5 (16.7) |
Comorbidities (Yes/no/unkown, n/n/n) | |||
Lung disease | 1/9/0 | 0/7/3 | 0/0/10 |
Diabetes | 1/9/0 | 1/6/3 | 0/0/10 |
Heart disease | 1/9/0 | 2/5/3 | 0/0/10 |
Adiposity | 4/6/0 | 3/4/3 | 0/0/10 |
Hypertension | 2/5/3 | 2/4/4 | 0/0/10 |
Cardiovascular disease | 1/6/3 | 1/5/4 | 0/0/10 |
Renal insufficeincy | 1/6/3 | 1/5/4 | 0/0/10 |
Depression | 1/6/3 | 1/5/4 | 0/0/10 |
Liver disease | 1/6/3 | 0/6/4 | 0/0/10 |
Obstructive lung disease | 1/6/3 | 0/6/4 | 0/0/10 |
Chronic therapy (Yes/no/unkown, n/n/n) | |||
Cortisone | 2/8/0 | 0/7/3 | 0/0/10 |
Immunosuppressive drugs | 2/8/0 | 0/7/3 | 0/0/10 |
Place of birth (Europe/other/unkown, n/n/n) | 4/3/3 | 5/1/4 | 0/0/10 |
Smoking status (never-/ex-/unkown, n/n/n) | 5/2/3 | 4/3/3 | 0/0/10 |
Day of sampling (disease day, median (IQR)) | 8.5 (5.8–25.8) | 12.0 (7.0–18.0) | – |
Acute COVID-19 therapy (n (%)) | |||
ICU | 10 (33.3) | 3 (10.0) | – |
Ventilation | 10 (33.3) | 5 (16.7) | – |
ECMO | 3 (10.0) | 0 (0.0%) | – |